From a $10 direct listing to a $150 S&P 500 constituent, Palantir's journey has been fueled by the AI boom. As government and commercial demand surge, analysts project staggering growth. But with sky-high valuations, the path forward requires navigating lofty expectations.
XPO's dual recognition of driver safety excellence coincides with significant institutional options activity targeting 2026, setting the stage for a pivotal period as the company navigates leadership change and high expectations for its core LTL business.
Popular, Inc. (BPOP) shares have rallied following robust 2025 results, driven by higher net interest income, EPS growth, and aggressive shareholder returns via dividends and buybacks. With the stock up nearly 20% in 90 days, investors are weighing whether its current valuation still offers an entry point.
Insulet (PODD) shares have faced significant pressure in recent months, diverging from the company's underlying business performance. This analysis delves into whether the current price weakness presents a buying opportunity for the Omnipod maker or reflects deeper market concerns about its premium valuation and growth sustainability.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
Missouri's inaugural month of legal sports betting attracted over $540 million in wagers, but aggressive promotions led to a net revenue loss for operators, even as the state collected millions in fees and taxes.
Axon Enterprise stock fell sharply this week, caught in a sector-wide downturn for software stocks driven by AI disruption fears and valuation concerns, despite a lack of company-specific negative news.
Amidst economic crosscurrents, a closer look at Ideal Power, NetSol Technologies, and Sono-Tek reveals companies executing distinct strategies to navigate growth and profitability challenges in the high-risk, high-reward penny stock arena.
American Express reported fourth-quarter earnings that slightly trailed analyst forecasts, prompting a share price decline. Despite the near-term miss, the company issued strong forward guidance for 2026 and announced a significant dividend hike, underscoring confidence in its long-term growth trajectory driven by card member spending and fee growth.
After soaring to unprecedented highs, copper prices have begun to retreat. Goldman Sachs forecasts a more significant market adjustment by mid-2026, driven by potential U.S. tariff policies and a disconnect from fundamental demand.
Financial planners are urging a shift in mindset: the date on your retirement party invitation matters less than the balance in your investment portfolio. We break down the calculations that show whether you're truly ready to leave the workforce.
A stunning reversal wiped out months of gains for precious metals on Friday, with gold futures tumbling to $4,800 and silver recording a historic single-day drop, sparking fears of a volatile new phase for commodity markets.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
The White House has backed away from plans to set minimum prices for domestic critical minerals projects, telling industry leaders that ventures must stand on their own financially. The policy reversal, driven by funding uncertainties and market concerns, marks a significant shift in strategy for bolstering the U.S. supply chain.
Shares of diabetes care innovator Insulet have tumbled nearly 10% year-to-date, sparking a fierce debate among investors. While a key valuation model suggests the stock is deeply undervalued, its sky-high P/E ratio tells a conflicting story. We examine the numbers and what they mean for the future of the Omnipod maker.
DoubleVerify's nomination for a Digiday award spotlights its News Accelerator initiative, a strategic push to bolster quality journalism and advertiser confidence in digital news environments. The move comes as the industry grapples with brand safety and seeks more transparent ad placements.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Despite a sharp pullback following gold's price dip, analysts remain bullish on SSR Mining, citing strong earnings potential and attractive valuation metrics even after its stellar run.
A pivotal week in business saw Tesla's long-awaited robotaxis begin operations without safety drivers, signaling a new phase in autonomous mobility. Meanwhile, Greg Abel's early moves at Berkshire Hathaway hint at a potential strategic shift, and a push for tokenized, round-the-clock stock trading raises questions about the future of finance.
